Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D. Lambkin-Williams R, et al. PLoS One. 2016 Dec 22;11(12):e0163089. doi: 10.1371/journal.pone.0163089. eCollection 2016. PLoS One. 2016. PMID: 28005959 Free PMC article. Clinical Trial.
Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.
Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, Eze K, Balaratnam G, Borley DW, Gilbert A, Lambkin-Williams R. Fullen DJ, et al. PLoS One. 2016 Jan 13;11(1):e0145902. doi: 10.1371/journal.pone.0145902. eCollection 2016. PLoS One. 2016. PMID: 26761707 Free PMC article. Clinical Trial.
Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.
Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus AD, Knight A, Oxford JS, Lapini G, Cox R, Lambkin-Williams R. Mann AJ, et al. PLoS One. 2014 May 21;9(5):e93761. doi: 10.1371/journal.pone.0093761. eCollection 2014. PLoS One. 2014. PMID: 24850536 Free PMC article.
A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
Pleguezuelos O, Robinson S, Fernández A, Stoloff GA, Mann A, Gilbert A, Balaratnam G, Wilkinson T, Lambkin-Williams R, Oxford J, Caparrós-Wanderley W. Pleguezuelos O, et al. Clin Vaccine Immunol. 2015 Jul;22(7):828-35. doi: 10.1128/CVI.00098-15. Epub 2015 May 20. Clin Vaccine Immunol. 2015. PMID: 25994549 Free PMC article. Clinical Trial.
A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
Fullen DJ, Murray B, Mori J, Catchpole A, Borley DW, Murray EJ, Balaratnam G, Gilbert A, Mann A, Hughes F, Lambkin-Williams R. Fullen DJ, et al. PLoS One. 2016 Dec 9;11(12):e0166113. doi: 10.1371/journal.pone.0166113. eCollection 2016. PLoS One. 2016. PMID: 27936016 Free PMC article. Clinical Trial.
Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases.
Bueno de Mesquita PJ, Nguyen-Van-Tam J, Killingley B, Enstone J, Lambkin-Williams R, Gilbert AS, Mann A, Forni J, Yan J, Pantelic J, Grantham ML, Milton DK. Bueno de Mesquita PJ, et al. Among authors: lambkin williams r. Influenza Other Respir Viruses. 2021 Jan;15(1):154-163. doi: 10.1111/irv.12790. Epub 2020 Jul 23. Influenza Other Respir Viruses. 2021. PMID: 32705798 Free PMC article.
42 results